Therapeutic effect of mizoribine on pemphigus vulgaris and pemphigus foliaceus
- 1 July 2012
- journal article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 25 (4), 382-385
- https://doi.org/10.1111/j.1529-8019.2012.01469.x
Abstract
We evaluated the effectiveness of mizoribine, a newly developed immunosuppressive agent, as an adjuvant therapy in the treatment of both pemphigus vulgaris and pemphigus foliaceus. Eleven pemphigus patients (eight pemphigus vulgaris and three pemphigus foliaceus) received the combination therapy of prednisolone and mizoribine. Complete remission was observed in three of the eight patients with pemphigus vulgaris and in one of the three patients with pemphigus foliaceus. The four patients with complete remission had a rapid clinical response and achieved remission at a median of 11.8 months. Partial remission was achieved in two of the three patients with pemphigus foliaceus. The median time to achieve partial remission was 16.0 months. Six (55.6%) of the 11 patients with pemphigus had complete or partial remission and were able to taper their prednisolone. The cumulative probability of having a complete remission was 64.3% at 19 months of follow-up using Kaplan-Meier analysis. The effectiveness of the additional mizoribine therapy could be attributed to its corticosteroid-sparing properties as well as its immunosuppressive effects. The serum concentration titer of mizoribine was around 1.0 μg/mL 2 hours after administration. Patients who were not improved by the additional mizoribine might require a continuously higher dose of mizoribine to achieve effective therapy.Keywords
This publication has 15 references indexed in Scilit:
- Use of mizoribine in two patients with recalcitrant cutaneous polyarteritis nodosaJournal of the American Academy of Dermatology, 2011
- What’s new in i.v. immunoglobulin therapy and pemphigus: High-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigusThe Journal of Dermatology, 2010
- New algorithm (KAWAKAMI algorithm) to diagnose primary cutaneous vasculitisThe Journal of Dermatology, 2010
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- Treatment strategies for pemphigus vulgaris in JapanExpert Opinion on Pharmacotherapy, 2008
- d‐penicillamine‐induced pemphigus successfully treated with combination therapy of mizoribine and prednisoloneJournal of Dermatological Treatment, 2004
- Mizoribine oral pulse therapy for patients with disease flare of lupus nephritisClinical Nephrology, 2003
- Functional Interaction of the Immunosuppressant Mizoribine with the 14-3-3 ProteinBiochemical and Biophysical Research Communications, 2000
- Adhesion Molecules. I: Keratinocyte-Keratinocyte Interactions; Cadherins and PemphigusJournal of Investigative Dermatology, 1995
- Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.JCI Insight, 1991